Journals / Sağlık Bilimlerinde İleri Araştırmalar Dergisi / 2021 / Cilt: 4 - Sayı: 2

Myelodysplastic Syndrome in Children

Çocuklarda Miyelodisplastik Sendrom

Pages
75–80
Publication Date
2021-06-21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, MDS in childhood is described by comparing it with adult MDS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myelodysplastic syndrome (MDS); is a clonal stem cell disorder characterized by cytopenia, dysplasia and ineffective erythropoiesis.
📊
Key Findings & Data:Unexplained prolonged cytopenia, dysplasia in at least one series, clonal cytogenetic anomaly and increased blasts are diagnostic criteria, and the presence of at least two guides diagnosis.
💡
Conclusion & Impact:In this article, MDS in childhood is described by comparing it with adult MDS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Miyelodisplastik sendrom · Çocuk · Displazi

Abstract

Myelodysplastic syndrome (MDS); is a clonal stem cell disorder characterized by cytopenia, dysplasia and ineffective erythropoiesis. MDS is very rare in children compared to adults. In myelodysplastic syndrome, complaints related to cytopenia such as bleeding, infection, and pallor are the most common. Diagnosis is made through clinical findings, morphology, immunophenotype and cytogenetic methods. Unexplained prolonged cytopenia, dysplasia in at least one series, clonal cytogenetic anomaly and increased blasts are diagnostic criteria, and the presence of at least two guides diagnosis. There are important differences between childhood and adult MDS in terms of classification, underlying diseases and treatment approaches. In this article, MDS in childhood is described by comparing it with adult MDS.

Özet

Miyelodisplastik sendrom (MDS); sitopeni, displazi ve inefektif eritropoyez ile karakterize klonal bir kök hücre bozukluğudur. Çocuklarda MDS erişkinlere göre oldukça nadir görülür. Miyelodisplastik sendromda en sık sitopeni ile ilişkili şikayetler görülür. Kanama, enfeksiyon ve solukluk sık bulgulardır. Tanı klinik bulgular, morfoloji, immünfenotip ve sitogenetik tetkiklerle konulur. Açıklanamayan uzun süren sitopeni, en az bir seride displazi, klonal sitogenetik anomali ve artmış blast sayısı tanı kriterleridir ve en az ikisinin olması tanıda yol göstericidir. Çocukluk çağı ve erişkin MDS arasında hem sınıflama, hem altta yatan hastalıklar hem de tedavi yaklaşımları açısından önemli farklılıklar vardır. Bu yazıda erişkin dönemde ortaya çıkan MDS ile karşılaştırılarak çocukluk çağında MDS anlatılmıştır.

🔖

Cite This Article

ÖZDEMİR, G. (2021). Myelodysplastic Syndrome in Children. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, Cilt: 4 - Sayı: 2, 75–80. https://ajindex.com/articles/217114

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Baumann I, Niemeyer C, Benett J. Childhood myelodysplastic syndrome. In: Swerdlow S, Campo E, Harris N, al e, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid tissues. Lyon: IARC Press
  2. Hasle H, Baumann I, Bergstrasser E et al. The international prognostic scoring system (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004
  3. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012
  4. 120(12):2454-65. 4.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press
  5. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009
  6. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 2016
  7. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, Head DR. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases.Leukemia 2003
  8. 17(2):277-82. 8.Kardos G, Baumann I, Passmore SJ et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003
  9. 102(6):1997-2003. 9.Gohring G, Michalova K, Beverloo HB et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood 2010
  10. 116(19):3766-69. 10.Wlodarski MW, Hirabayashi S, Pastor V et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood 2016
  11. 127(11):1387-97. 11.Schwartz JR, Wang S, Ma J et al. Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome. Leukemia 2017
  12. 31(8):1827-30. 12.Yoshimi A, Niemeyer C, Baumann I, Schwarz-Furlan S, Schindler, Detlev S, Wolfram E, Brigitte S. High incidence of Fanconi Anemia in patients with a morphological picture consistent with refractory cytopenia of childhood. Br J Haematol 2013
  13. 160(1):109-11. 13.Aalbers, AM, van den Heuvel-Eibrink MM, Baumann I et al. T-cell receptor Vβ skewing frequentl